Just a few years ago, Tenet was overshadowed nearly to invisibility by the Columbia/HCA juggernaut. Now it has reversed roles, and suppliers have come courting. But instead of playing by traditional group purchasing rules, Tenet hopes to make its mark by going in the opposite direction from everyone else, shaking up a stagnant industry.
by David Cassak
Join thousands of industry professionals who rely on In Vivo for daily insights
Already a subscriber?
Ochre Bio co-founder and CSO Quin Wills spoke with In Vivo about the UK-based company's novel approach to finding RNA therapies for chronic liver disease.
As GLP-1 agonists surge to blockbuster status transforming diabetes and obesity treatment, Richard DiMarchi, the pioneering scientist behind their development, recounts the inside story of the drug class in a fireside chat.
João Ribas combines scientific expertise with venture capital at Novo Holdings, applying his dual background to develop biotech investments that connect academic research with commercial opportunity.
